Subscribe To

Price Alert Latest News Economic Calendar News

CNTX / Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting

Context Therapeutics (NASDAQ:CNTX) Inc announced that an abstract regarding its preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida. The clinical-stage biopharmaceutical company said on April 17, 2023, at 4:30 PM EDT, it will host a webinar with its management team and AACR presenter, Dr Rucker, to discuss the results from this presentation, provide updates on the CTIM-76 preclinical program, and answer questions from investors. Read More

Demo Live Account See Partner Details

Content Topics

Context

Therapeutics

Says

Ctim

76 Abstract

Accepted

Ctim 76

Presentation

Annual

Meeting

Stock

CNTX

Posted: Mar 15 2023, 09:16

Author Name: Proactive Investors

CNTX News

By Proactive Investors
October 31, 2023

Context Therapeutics reveals ‘encouraging' preclinical data for CTIM-76 tumor treatment

Context Therapeutics (NASDAQ:CNTX) Inc has announced what it called encouraging preclinical data regarding its preclinical asset, CTIM-76, a Claudin 6

By Proactive Investors
August 10, 2023

Context Therapeutic says it has enough cash to fund operation into late 2024

Context Therapeutics (NASDAQ:CNTX) Inc. has announced its financial results for the second quarter ended June 30, 2023, highlighting that it has suffi

By Proactive Investors
May 11, 2023

Context Therapeutics says focus on preclinical cancer therapeutic extends cash runway into late 2024

Context Therapeutics said its decision made during the first quarter to focus on developing its preclinical asset CTIM-76 has extended the company's c

By Proactive Investors
April 16, 2023

Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting, will host webinar

Context Therapeutics (NASDAQ:CNTX) Inc announced that an abstract regarding its preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody,

By Proactive Investors
March 23, 2023

Context Therapeutics announces pipeline update with FY 2022 financial results

Context Therapeutics (NASDAQ:CNTX) has announced a portfolio prioritization and capital allocation strategy that is expected to extend its cash runway

By Proactive Investors
March 15, 2023

Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting

Context Therapeutics (NASDAQ:CNTX) Inc announced that an abstract regarding its preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody,

By Proactive Investors
February 6, 2023

Context Therapeutics highlights clinical responses from clinical trial evaluating ONA-XR to treat endometrial cancer

Context Therapeutics (NASDAQ:CNTX) Inc has highlighted encouraging clinical responses from its Phase 2 OATH clinical trial evaluating ONA-XR to treat

By Proactive Investors
January 9, 2023

Context Therapeutics announces manufacturing agreement with Lonza for bispecific antibody targeting Claudin 6 positive cancers

Context Therapeutics (NASDAQ:CNTX) Inc said it will be collaborating with Lonza, a global development and manufacturing partner to the pharma, biotech

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.